Ian Clark Sells 14,180 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Ian Clark sold 14,180 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the completion of the sale, the director directly owned 2,975 shares in the company, valued at approximately $472,787. This trade represents a 82.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Guardant Health Trading Down 3.4%

GH opened at $157.58 on Friday. The company has a 50 day moving average of $146.24 and a 200 day moving average of $114.82. The company has a market cap of $21.15 billion, a PE ratio of -45.15 and a beta of 1.60. Guardant Health, Inc. has a 12 month low of $48.25 and a 12 month high of $176.58.

Institutional Investors Weigh In On Guardant Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC grew its position in Guardant Health by 14.5% during the second quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock valued at $145,000 after acquiring an additional 122 shares during the last quarter. First Pacific Financial lifted its holdings in shares of Guardant Health by 33.1% in the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after acquiring an additional 139 shares during the last quarter. Xponance LLC lifted its holdings in shares of Guardant Health by 2.1% in the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock worth $984,000 after acquiring an additional 199 shares during the last quarter. Danske Bank A S boosted its stake in shares of Guardant Health by 20.0% in the 4th quarter. Danske Bank A S now owns 1,200 shares of the company’s stock valued at $123,000 after purchasing an additional 200 shares in the last quarter. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna boosted its stake in shares of Guardant Health by 1.9% in the 4th quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company’s stock valued at $1,124,000 after purchasing an additional 200 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on GH. Citigroup increased their target price on Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Stifel Nicolaus boosted their price objective on Guardant Health from $130.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Stephens increased their price objective on Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a report on Tuesday. UBS Group set a $150.00 target price on Guardant Health in a research note on Wednesday, June 24th. Finally, Piper Sandler lifted their target price on Guardant Health from $135.00 to $193.00 and gave the company an “overweight” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.